tiprankstipranks
EMVision’s Neurodiagnostic Tech Shows Promising Study Results
Company Announcements

EMVision’s Neurodiagnostic Tech Shows Promising Study Results

EMvision Medical Devices Ltd. (AU:EMV) has released an update.

Don't Miss Our Christmas Offers:

EMVision Medical Devices Ltd has announced impressive results from its groundbreaking neurodiagnostic technology designed to identify strokes and their types early. The EMView study, involving 307 participants, showed high sensitivity and specificity in detecting hemorrhagic and ischemic strokes, paving the way for a validation trial aimed at FDA clearance and commercialization. The trial is expected to cost $4 million and take 6-12 months, backed by the company’s cash reserves.

For further insights into AU:EMV stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App